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Patients with estrogen receptor (ER)+/progesterone receptor (PR) and/or HER-2 overexpressing breast
carcinomas may derive lower benefit from endocrine treatment. We examined retrospectively data from 972
breast cancer patients who received tamoxifen (725), tamoxifen + Gn-RH analogs (127) and aromatase
inhibitors (120) as adjuvant treatments. ER+/PR versus ER+/PR+ tumours were characterised by larger size
(P = 0.001), higher tumour grade (P = 0.001), higher Ki-67 expression (P = 0.001) and lower mean ER
(P = 0.000) and HER-2 expression (P = 0.000). At univariate analysis, tumour grading [hazard ratio (HR) = 4.0;
95% confidence interval (CI) = 1.4–11.1; P = 0.007], nodal status (HR = 3.4; 95% CI 1.2–5.7; P = 0.000), tumour
diameter (HR = 2.9; 95% CI 1.7–4.7; P = 0.000) lack of PR expression (HR = 2.1; 95% CI 1.3–3.4; P = 0.002)
and HER-2 overexpression (HR = 1.9; 95% CI 1.0–3.5; P = 0.03), as well as Ki 67 expression (HR = 1.7; 95% CI
1.0–2.7; P = 0.04) were associated with shorter disease-free survival (DFS). At the multivariate analysis, nodal
status (HR = 3.6; 95% CI 1.9–6.8; P = 0.0001), lack of PR expression (HR = 2.3; 95% CI 1.3–4.0;
P = 0.003) and tumour diameter (HR = 2.1; 95% CI 1.1–3.8; P = 0.018) retained their prognostic significance,
whereas HER-2 overexpression was associated with a trend towards shorter DFS that was of borderline
statistical significance (HR = 2.0; 95 % CI 1.0–3.9; P = 0.05). Our data suggest that lack of PR expression
and HER-2 overexpression are both associated with aggressive tumour features, but the prognostic information
of PR status on the risk of recurrence in endocrine-treated breast cancer patients is stronger.
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introduction
New molecular technologies have provided the experimental
basis to confirm that the variability of breast cancer outcome
largely depends on its intrinsic biologic heterogeneity. Therefore,
breast cancer is currently considered as not a single, but instead
a spectrum of diseases characterised by their own molecular
features, aggressiveness and response to treatments [1].
Endocrine sensitivity, assessed by the expression of the
estrogen receptor (ER) and/or progesterone receptor (PR), has
long been the only recognised and validated predictive factor to
guide therapeutic decisions. The Oxford overview on adjuvant
therapies for breast cancer clearly shows that the benefit of
endocrine treatment is limited to patients with tumours
expressing the ER and/or PR [2]. The degree of endocrine
sensitivity is currently quantified by immunohistochemistry
(IHC), and may be expressed as the percentage of cells stained
after treatment with anti-ER/PR antibodies. According to the
conclusions reached at the Consensus Conference held by the
National Cancer Institute in the year 2000, all tumours with at
least 1% of cells expressing the ER/PR are considered as
potentially endocrine sensitive [3].
More recently, also the overexpression of the HER-2
(c-erbB-2/neu) oncogene has been recognised as a significant
variable for the assessment of breast cancer prognosis and
response to treatments in the metastatic and adjuvant
settings [4, 5]. Therefore, a different clinical management is
now reserved to HER-2 overexpressing (HER-2+) versus HER-2
nonoverexpressing (HER-2), as it is for ER positive (ER+)
and/or PR positive (PR+) versus ER negative (ER) and PR
negative (PR) tumours [6].
Several retrospective studies suggest that HER-2+ tumours
may be less sensitive to endocrine treatments and, namely, to
tamoxifen. This finding has been attributed to the existence of
a cross talk between the ER and HER-2 metabolic pathways [7]
and to the detection of lower absolute levels of ER when HER-2
is amplified/overexpressed [8]. In postmenopausal women,
third generation aromatase inhibitors (AIs) have successfully
challenged the prominent role of tamoxifen as treatment of
choice both in the adjuvant and metastatic settings [9].
According to preliminary data, the advantage of AIs over
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tamoxifen could be more relevant in the subgroups of
ER+/PR and HER-2+ tumours [10–13].
The aim of our study is to verify the influence of PR and
HER-2 status on the clinical and pathological characteristics of
a consecutive series of largely ER+ breast cancer patients and to
assess whether these two variables are associated with the
outcome of patients receiving adjuvant endocrine treatment.
subjects and methods
study population
Cases were selected by an institutional database containing all patients
treated for primary breast cancer at the Academic Division of
Gynaecological Oncology, University of Turin. Out of 2259 treated since
January 1988 to January 2005, 972 consecutive patients who received
adjuvant endocrine treatment, and for whom clinical–pathological data
and updated follow-up information were available, were included in
the study.
Microscopic tumour size, tumour grading according to Elston and Ellis
[14] and nodal involvement were assessed on sections stained with
conventional hematoxylin and eosin. IHC was used to measure ER and PR
expression (>1% of the cell staining was coded as positive) and cell
proliferation by Ki-67 (<20% was coded as low; ‡20% as high). HER-2
overexpression was assessed as the percentage of cell stained by two Food
and Drug Administration approved tests (CB 11, Ventana Medical System
Inc., Tucson, AZ, until 2000 and Herceptest, DAKO, Corp., Carpinteria, CA,
thereafter). The cut-off for HER-2 overexpression was set at ‡40% cells
stained because it allowed the best discrimination between relapsing and
nonrelapsing patients.
Surgical treatment consisted in wide local excision plus axillary dissection
followed by whole breast radiotherapy plus a boost on the tumour bed, or
modified radical mastectomy when breast-conserving surgery was not
indicated. After mastectomy, only selected high-risk patients received
radiotherapy to the chest wall and supraclavicular nodes. In our institution,
sentinel node biopsy became standard treatment of clinically node negative
patients in 1999; since then, completion axillary dissection was carried out
only in case of micro- and macrometastatic sentinel node.
Adjuvant treatments of patients not enrolled in clinical-controlled studies
were prescribed on the basis of international guidelines and consensus
conferences (Table 1). In general, all patients with ER and/or PR expression
>1% were prescribed endocrine treatment with tamoxifen 20 mg/day
for 5 years. Premenopausal women also received ovarian inhibition by
Gn-RH analogs for 2 years. Since 2001, postmenopausal patients with
contraindication or intolerance to tamoxifen received an AI for 5 years. Most
of the patients with axillary nodal involvement, <70 years of age and no
significant morbidity, received adjuvant chemotherapy before the
commencement of endocrine treatment. Node-negative patients underwent
chemotherapy if classified as at intermediate/high risk on the basis of
tumour size, grading and age. Most common cytotoxic therapies were
represented by non-antracyclin-containing combinations [combination
chemotherapy with cyclophosphamide, methotrexate and fluorouracil
(CMF) q1:8:28 · six cycles], antracyclin-containing combinations
½adriamycin, clycophosphamide (AC) q1:21 · four cycles; fluorouracil,
epirubicin/adriamycin, cyclophosphamide (FEC/FAC) q1:21 · six cycles;
epirubicin q21 · four cycles followed by CMF q1:8:28 · four cycles)
(E-CMF) and antracyclin–taxane combinations [AC q1:21 · four cycles
followed by paclitaxel (Taxol) q1:21 · four cycles].
All patients signed a written informed consent stating that their clinical
data and biological material could be used for research purposes and the
study received institutional board approval.
statistical analysis
The clinical and pathologic characteristics of women in study are reported as
frequencies, means and ranges. Quantitative variables were compared by the
Pearson’s chi-square test or with the Fisher’s exact test when required.
Qualitative variables were compared by the analysis of variance. Normality
of the variables’ distribution was tested by the Kolmogorov–Smirnov test.
For non-normally distributed variables, a nonparametric analysis was
carried out with the Mann–Whitney U test.
The primary outcome was disease-free survival (DFS) defined as the
length of time from the date of surgery to first local or distant recurrences
(contralateral cancers not included) for relapsing patients, while the others
were censored at the time of last follow-up or death. Median follow-up was
35 months (range 1–205). Overall survival was not calculated as too few
events (deaths) were recorded. DFS curves were estimated using the Kaplan–
Meier method and were compared by the log-rank test. A univariate Cox
regression model was used to determine the association of variables with
DFS. Hazard ratios (HRs) are presented with their 95% confidence intervals
(CIs). The assumption that regression coefficients are constant over time was
verified by testing the variables for the lack of proportionality and by
examining the smoothed plots of the rescaled Schoenfeld residuals and
pointwise 95% confidence bands for each variable as described by
Hilsenbeck et al. [15]. The independent value of these variables was assessed
in multivariable Cox regression model, including the potential interaction
between ER/PR status and HER-2 status. Statistical analyses were carried out
using the SPSS software, version No. 9. All statistical tests were two-sided,
and a P value <0.05 was deemed statistically significant.
results
Table 2 shows the mean distribution of clinical and pathological
variables in the whole series of 972 patients. Due to the criteria
Table 1. Adjuvant endocrine and cytotoxic treatments
Type of treatment n %
Endocrine therapy (6chemotherapy) 972 100
Tamoxifen 725 74.6
Tamoxifen + Gn-RH analogs 127 13.0
Aromatase inhibitors 120 12.3
Chemotherapy (+endocrine therapy) 382 39.3
Table 2. Mean distribution of clinical and pathological characteristics
Variable No. tested Mean Median Range
Age (years) 962 60.0 60.5 20–90
Tumour diameter (mm) 945 20.9 18 0.1–10
No. involved axillary nodes 839 2.5 0 0–45
Grading 848 2.0 2 1–3
ER (per cent positive
cells at IHC)
942 67.2 70.5 0–100
PR (per cent positive
cells at IHC)
936 41.3 50 0–100
HER-2 (per cent positive
cells at IHC)
877 11.9 0 0–100
Ki 67 (per cent positive
cells at IHC)
810 15.7 12 0–85
ER, estrogen receptor; IHC, immunohistochemistry; PR, progesterone
receptor.
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used for patients’ selection, the mean percentage of cells
expressing ER was high. Also the low percentage of HER-2
expressing cells, as well as the low proliferative index measured
by Ki-67 are in line with the selection criteria which favoured
endocrine sensitive and slowly growing tumours.
tumour characterisation according to PR and
HER 2 status
Older patients had lower PR expression, while patients with
HER-2+ tumours were slightly younger, although not
significantly. PR tumours were characterised by larger size as
compared to PR+ tumours, as well as HER-2+ versus HER-2
tumours, but again this difference did not reach statistical
significance. PR and HER-2+ tumours showed higher
proliferative activity measured by Ki-67 and higher tumour
grade as compared with PR+ and HER-2 tumours,
respectively. Conversely, nodal involvement was not influenced
by both PR and HER-2 status (Table 3).
correlation between ER, PR and HER-2 status
Overall, 76% of the tumours showed both ER and PR expression
(ER+/PR+), 18% ER expression only (ER+/PR), 3.5% PR
expression only (ER/PR+), while none of the two receptors
was expressed in 3.5% of the patients (ER/PR).
The levels of both ER and PR were inversely correlated with
HER-2 overexpression (Table 4). In particular, HER-2+
tumours were more represented in ER+/PR versus ER+/PR+
tumours (39.0% versus 17.7%; P = 0.000); accordingly, the
mean percentage of HER-2+ cells was significantly higher in
ER+/PR versus ER+/PR+ tumours (21.4% versus 9.2%;
P = 0.000).
clinical outcome according to clinical–pathological
variables
At the univariate analysis of survival, lack of PR expression
(Figure 1) and HER-2 overexpression (Figure 2) as well as nodal
status, tumour diameter, tumour grading and Ki-67 expression
showed a significant association with shorter DFS (Table 5),
even after controlling for continuous levels of ER expression
(data not shown). All the other variables, including the
administration of adjuvant chemotherapy, did not
influence DFS.
In the multivariate Cox model including all variables, nodal
status (HR = 3.6; 95% CI 1.9–6.8; P = 0.0001), lack of PR
expression (HR = 2.3; 95% CI 1.3–4.0; P = 0.003) and tumour
diameter (HR = 2.1; 95% CI 1.1–3.8; P = 0.018) retained their
prognostic significance. HER-2 overexpression was associated
with a trend towards worse DFS that resulted of borderline
statistical significance (HR = 2.0; 95 % CI 1.0–3.9; P = 0.05).
We then conducted a subset analysis to evaluate whether the
prognostic value of HER-2 overexpression differed in the
subgroups of ER+/PR+ and ER+/PR tumours. Indeed, it
appeared that the prognostic significance of HER-2
overexpression was restricted to the latter group of patients
(HR = 2.4; 95% CI 1.1–5.3; P = 0.04), whereas no significant
effect of HER-2 status was evident for ER+/PR+ patients
(HR = 0.8; 95% CI 0.3–2.8; P not significant).
Table 3. Clinical–pathological characteristics according to PR and HER-2 status
Variable PR+a PR P value HER 2 HER 2+b P value
Age
No. tested 735 190 749 117
Mean (range) 59.4 (29–90) 62.7 (33–87) 0.001 60.2 (29–90) 58.7 (30–84) NS
<50 years (%) 25.0 12.6 22.3 26.5
‡50 years (%) 75.0 87.4 0.000 77.7 73.5 NS
Tumour size
No. tested 727 189 745 115
<2 cm (%) 57.4 42.9 55.2 47.0
‡2 cm (%) 42.6 57.1 0.001 44.8 53.0 NS
Nodal status
No. tested 636 171 645 112
Negative (%) 55.0 48.0 54.1 51.8
Positive (%) 45.0 52.0 NS 45.9 48.2 NS
Tumour grading
No. tested 658 168 676 106
G1 (%) 23.9 14.9 23.7 7.7
G2 (%) 46.5 40.5 46.2 34.6
G3 (%) 29.6 44.6 0.001 30.1 57.7 0.000
Ki 67 expression
No. tested 651 154 671 99
Low (<20%) 71.3 57.1 72.0 47.5
High (‡20%) 28.7 42.9 0.001 28.0 52.5 0.000
PR, progesterone receptor; NS, not significant.
aPR+, ‡1% stained cells.
bHER-2+, ‡40% stained cells.
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analysis of PR and HER-2 status as
time-dependent variables
Although a significant difference in DFS was found according to
PR status, the survival curves cross at 96 months of follow-up.
The time-dependent nature of the prognostic information
provided by PR was confirmed by the violation of the
proportional hazard assumption in the Cox regression model
(P = 0.001), with the time-varying curve crossing the null line
(crossover effect). As depicted in Figure 3, PR expression is
protective for early relapse, but changes at 3.5 years of
follow-up indicating a switch to poor prognosis. A formal test
for lack of proportionality suggests that also the HR of HER-2
status is not constant, but it decreases with time (P = 0.027).
Nevertheless, the time-varying curve never dips below the null
value indicating that HER-2 overexpression continues to carry
unfavourable prognostic value with longer follow-up (Figure 4).
Similarly, none of the other significant variables at the
univariate analysis of survival showed a crossover effect like that
of PR. Crossover violations of the proportional hazard
assumption are more important to detect and model explicitly;
therefore, we tried to add PR as time-dependent covariate in the
Cox model, but since we did not obtain significant variations
of the results, this violation was ignored in the final model.
discussion
Our study confirms that lack of PR expression and HER-2
overexpression are both associated with aggressive tumour
features in predominantly ER+ breast carcinomas. PR
expression is generally considered a marker of integrity of the
estrogenic metabolic pathway as it requires the activation of the
ER. The lower mean percentage of ER-stained cells in PR as
compared to PR+ tumours found in our study is in line with this
hypothesis and with the literature data.
Lower mean levels of ER and PR were also found in HER-2+
versus HER-2 tumours. It has been hypothesised that HER-2
overexpression may interact with some of the metabolic
pathways triggered by the activation of the ER [16]. A possible
explanation for the lower PR concentration in the presence of
HER-2 overexpression is the activation of the P13K–Akt–mTor
pathway by an increased growth factor activity. It has been
reported that this pathway can actually reduce the expression
of PR at the transcriptional level by activating the AP-1 site in
the PR gene promoter [17].
Biological and clinical data suggest that lack of PR expression
and HER-2 overexpression may predict lower endocrine
sensitivity in ER+ tumours. In particular, the predictive value
of HER-2 status is highly debated: a subgroup analysis of the
Cancer and Leukemia Group B 8541 study [18] showed a lack
of interaction of tamoxifen use and HER-2 expression, whereas
in the large study by Arpino et al. [19], both PR and HER-2
independently predicted DFS; furthermore, in a recent
retrospective analysis of the National Atlantic Treaty
Organsation and Cancer Research Campaign adjuvant trials,
HER2-positive patients failed to benefit from tamoxifen
treatment [20].
In our series, both PR and HER-2 status as well as other
established prognostic markers like nodal involvement, tumour
Table 4. Correlation between HER-2 status and levels of ER and
PR expression
Variable HER-2 status P
Negative (0–1+) Positive (2–3+)
ER expression
No. tested 755 120
Mean levelsa 69.7% 53.3% 0.000
PR expression
No. tested 752 121
Mean levelsa 43.3% 29.5% 0.000
ER, estrogen receptor; PR, progesterone receptor.
aExpressed as the mean percentage of cells stained at
immunohistochemistry.
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Figure 1. Kaplan–Meier curves for disease-free survival according to
progesterone receptor status (0%: negative; ‡1%: positive).
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Figure 2. Kaplan–Meier curves for disease-free survival according to
HER-2 status (<40% negative; ‡40% positive).
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diameter, grading and Ki-67 expression were associated with
reduced DFS in patients who underwent endocrine therapy.
Nevertheless, at the multivariate analysis of survival, PR status
showed a much stronger association with DFS as compared to
HER-2; furthermore, the unfavourable prognostic value of
HER-2 overexpression was restricted to ER+/PR and not to
ER+/PR+ patients, as suggested also by others [19].
The absence of PR expression has been interpreted as
a surrogate marker for HER-2 activation. This hypothesis has
been questioned by a recent study [21] showing that ER+/PR
tumours and HER-2+ tumours represent distinct patient
subgroups and concluding that alternative mechanisms must
underpin tamoxifen resistance in PR tumours. Both this study
and ours do not include a no-treatment arm which would be
required in order to ascertain the existence of a true endocrine
resistance in HER-2+ and/or ER+/PR tumours, yet they
suggest caution before concluding that PR loss simply represents
an epiphenomenon of HER-2 overexpression or that these
markers provide comparable predictive information.
The borderline significance of HER-2 overexpression as an
independent predictor of DFS could be due to the smaller
sample size of our study as compared to the study of Arpino
et al. [19], but their patient population also differed in two
important aspects. First, 25% of our patients received other
hormonal drugs in addition (Gn-RH) or instead of (AIs)
tamoxifen, whereas in their study tamoxifen was the only
adjuvant treatment of all patients. The inclusion of patients who
received different treatments might have obscured the selective
influence of HER-2 status on tamoxifen efficacy. Furthermore,
as our selection criteria included all patients who received
endocrine treatment, a small percentage of tumours displayed
ER/PR+ (3.5%) and also ER/PR (2.4%) phenotypes, which
were not represented in their study. Unfortunately, by
restricting the analysis to ER+ patients who received tamoxifen
as the sole endocrine treatment, both PR and HER-2 status
would loose their association with DFS in our series. Since the
study was not designed to test tamoxifen resistance, but instead
to assess the prognostic/predictive value of PR and HER-2
status, we decided to include all patients who received some
form of endocrine treatment.
The time dependence of the prognostic value of ER status has
been repeatedly reported in the literature [15, 22]; our data on
PR are consistent with a real change in the relative effect of
hormone receptors as a function of time. A retrospective
analysis of the arimidex, tamoxifen, alone and in combination
(ATAC) trial [10] suggests that the advantage of initial
treatment with anastrozole versus tamoxifen is greater for
ER+/PR as compared to ER+/PR+ patients. In addition,
>15% of ER+/PR patients on tamoxifen in this trial recurred
throughout the first 3 years. Interestingly, similar conclusions
were drawn by Tovey et al. [21], who showed that also HER-2
overexpression, as well as PR negativity, is a marker of
tamoxifen resistance in the first 3 years after primary treatment.
These studies suggest that PR and HER-2 expression identify
patients who exhibit de novo tamoxifen resistance since both
variables behave as time-dependent predictors of risk of relapse,
with a sharp decline of the risk after 3 years of tamoxifen
treatment. Therefore, the lack of significance of PR status when
patients switch to AIs after 2–3 years of tamoxifen reported by
Table 5. Univariate analysis of disease-free survival
Variable HR 95% CI P
Tumour diameter
‡2 cm versus <2 cm 2.9 1.7–4.7 0.000
Nodal status
Positive versus negative 3.4 1.2–5.7 0.000
Tumour grading
G2–G3 versus G1 4.0 1.4–11.1 0.007
Ki 67 expression
‡20% versus <20% 1.7 1.0–2.7 0.04
PR status
0% versus ‡1% 2.1 1.3–3.4 0.002
HER-2 expression
‡40% versus <40% 1.9 1.0–3.5 0.03
HR, hazard ratio; CI, confidence interval; PR, progesterone receptor.
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Figure 3. Time-dependent hazard ratio for progesterone receptor
(PR) ‡1 versus PR = 0 (solid line) and the corresponding pointwise 95%
confidence bands (vertical solid lanes). The dashed line represents
the null value.
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Figure 4. Time-dependent hazard ratio for HER-2 ‡40% versus
HER-2 <40% (solid line) and the corresponding pointwise 95%
confidence bands (vertical solid lanes). The dashed line represents
the null value.
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two large studies [23, 24] could be due to the fact that most
of the recurrences in PR tumours actually occur before the
switch. This finding was confirmed in our series where the
majority of the events in the PR-negative subset occurred within
the fourth year of follow-up. Conversely, the time-dependent
nature of the prognostic information of HER-2 overexpression
was less clear, although the small sample size of our study could
have hindered this specific effect.
In conclusion, our study confirms that PR status defines
a subset of tumours with distinctive pathological characteristics
andmay help select those patients who derive the greatest benefit
from endocrine adjuvant treatment, particularly within the
first few years of follow-up. HER-2 status carries a prognostic
information of borderline significance at the multivariate
analysis, although HER-2 overexpression is associated with
aggressive clinical and pathological features. Larger and
prospective studies are warranted to clarify this issue, given the
recent trend towards a widespread introduction of AIs and
trastuzumab in the adjuvant setting as first choice treatments of
ER+/PR and HER-2 positive tumours, respectively.
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